Clinical trial NCT04047836: Vaping High vs. Low Nicotine E-Liquid
Official title: Vaping High vs. Low Nicotine E-Liquid
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Cardiovascular Risk Factor
Nicotine Dependence
Keywords: E-Cigarettes
Vaping
E-Cig Mods
E-Liquid
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2019-08-07
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Crossover Assignment
Primary purpose: BASIC_SCIENCE

Brief summary: This study will examine the effects of electronic cigarette e-liquid nicotine content in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=36). The specific aim is to determine the impact of nicotine content of e-liquid on nicotine pharmacology, systemic exposure to toxic volatile organic compounds, and short-term cardiovascular effects.

Detailed description: This is a within-subjects, crossover design of advanced electronic cigarette users in which we will examine nicotine pharmacokinetics, subjective effects, daily nicotine intake and nicotine titration, short-term cardiovascular effects, and toxicant exposure when participants are using low vs. high nicotine e-liquids.

Hypothesis 1: E-cigarette users will titrate their intake of nicotine such that they will inhale fewer aerosol toxicants and suffer less harm to health when using higher vs. lower nicotine content e-liquids.

Hypothesis 2: Compared to low nicotine, high nicotine e-liquid use will have similar cardiovascular effects throughout the day (due to compensatory behavioral changes), with similar effects on heart rate, blood pressure, and catecholamine release.

Hypothesis 3: Exposure to volatile organic compounds (VOCs) will be lower when vaping high nicotine e-liquids compared to low nicotine e-liquids.

Eligibility criteria: Inclusion Criteria:

* Healthy on the basis of medical history and limited physical examination, as described below:
* Heart rate \< 105 beats per minute (BPM)\*
* Systolic Blood Pressure \< 160 and \> 90\*
* Diastolic Blood Pressure \< 100 and \> 50\*

  \*Considered out of range if both machine and manual readings are above/below these thresholds.
* Age: \>= 21 years
* Age: \<= 70 years
* Current regular user of open tank electronic cigarette (EC) (at least 20 times in the past 30 days) with e-liquid nicotine of 3-6 mg/mL.
* Non-smoker or non-daily cigarette smokers agreeing to abstain from cigarettes for the duration of the study.
* Saliva cotinine \>50 ng/mL and/or NicAlert=6
* Carbon monoxide \>= 5 ppm or per discretion of Principal Investigator

Exclusion Criteria:

* Medical
* Heart disease
* Seizures
* Cancer
* Thyroid disease (okay if controlled with medication)
* Diabetes
* Hepatitis B or C or Liver disease
* Glaucoma
* Kidney disease or urinary retention
* History of stroke
* An ulcer in the past year
* Active use of an inhaler for Asthma or Chronic obstructive pulmonary disease (COPD)
* Psychiatric conditions
* Current or past schizophrenia, and/or current or past bipolar disorder
* Major depression, current or within the past year
* Major personality disorder
* Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the PI and considered for inclusion
* History of psychiatric hospitalizations is not exclusionary, but study participation will be determined as per PI's approval
* Drug/Alcohol Dependence
* Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
* Positive toxicology test for illicit drugs at the screening visit (THC \& prescribed medications okay)
* Opioid replacement therapy (including methadone, buprenorphine, or other)
* Psychiatric medications
* Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRIs) and serotonin-norepinephrine reuptake Inhibitors (SNRIs) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate.
* Medications
* Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
* Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers)
* Concurrent use of nicotine-containing medications
* Any stimulant medications (example: Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment
* Other/Misc. Chronic Health Conditions
* Oral thrush
* Fainting (within the last 30 days)
* Other "life threatening illnesses" as per PI's discretion
* Pregnancy
* Pregnancy (self-reported and urine pregnancy test)
* Breastfeeding (determined by self-report)
* Concurrent participation in another clinical trial
* Inability to read and write in English
* Planning to quit vaping within the next 60 days
* Concurrent regular use of marijuana (occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study)
* Use of other tobacco products, smokeless tobacco, pipes, cigars/cigarillos, blunts/spliffs (no more than 10 times in the past month and must agree to abstain from their use during the period of the study)

Primary outcomes:
measure: Nicotine Exposure
timeFrame: Day 1 of each Arm
measure: Cardiovascular Effects: Heart Rate
timeFrame: Days 1-3 of each Arm
measure: Cardiovascular Effects: Systolic Blood Pressure
timeFrame: Day 2 of each Arm
measure: Cardiovascular Effects: Diastolic Blood Pressure
timeFrame: Day 2 of each Arm
Secondary outcomes:
measure: Vaping Topography: Puff Number
timeFrame: Days 1-3 of each Arm
measure: Vaping Topography: Puff Duration
timeFrame: Days 1-3 of each Arm
measure: Vaping Topography: Inter-Puff Interval
timeFrame: Days 1-3 of each Arm
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
city: San Francisco
country: United States
facility: Zuckerberg San Francisco General Hospital
state: California
Study officials:
affiliation: University of California, San Francisco
name: Neal Benowitz, MD
role: PRINCIPAL_INVESTIGATOR
References: